Top Page
Clover Biopharmaceuticals Ltd.
(2197)
Clover Biopharmaceuticals Ltd. (2197) vs. iShares MSCI Hong Kong ETF (EWH)
Clover Biopharmaceuticals Ltd. Business Overview & Revenue Model
Clover Biopharmaceuticals Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 38.42M | 39.26M | 0.00 | 0.00 | 0.00 | Gross Profit |
| -672.94M | 24.24M | -475.64M | -66.27M | 0.00 | EBIT |
| -951.21M | -144.40M | -2.45B | -6.01B | -909.92M | EBITDA |
| -916.54M | -45.07M | -2.39B | -2.23B | -335.04M | Net Income Common Stockholders |
| -903.43M | -138.54M | -2.45B | -6.02B | -915.87M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 427.53M | 752.97M | 1.64B | 2.87B | 806.51M | Total Assets |
| 812.74M | 2.10B | 4.69B | 5.35B | 1.19B | Total Debt |
| 89.64M | 334.45M | 354.37M | 67.92M | 22.32M | Net Debt |
| -311.60M | -401.41M | -1.25B | -2.70B | -493.87M | Total Liabilities |
| 2.45B | 2.83B | 5.36B | 4.13B | 2.17B | Stockholders Equity |
| -1.64B | -732.83M | -668.14M | 1.22B | -982.74M |
| Cash Flow | Free Cash Flow | |||
| -290.11M | -737.05M | -1.80B | -998.07M | 363.13M | Operating Cash Flow |
| -288.49M | -727.88M | -1.69B | -917.75M | 476.93M | Investing Cash Flow |
| 3.17M | -6.16M | -37.51M | 112.12M | -394.12M | Financing Cash Flow |
| -51.50M | -142.41M | 483.14M | 3.06B | 316.85M |
Clover Biopharmaceuticals Ltd. Technical Analysis
Clover Biopharmaceuticals Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $101.65B | 22.11 | 13.20% | 2.26% | -9.60% | -27.18% | |
74 Outperform | $113.92B | 31.58 | 8.17% | ― | 7.52% | -1.92% | |
72 Outperform | $991.98B | 6.84 | 7.49% | 11.71% | 37.04% | ||
62 Neutral | HK$3.78B | 21.21 | 4.47% | ― | -9.75% | ― | |
54 Neutral | $5.37B | 3.26 | -45.10% | 3.30% | 16.81% | 0.02% | |
47 Neutral | HK$79.35B | ― | 13.43% | -32.30% | -620.87% | ||
45 Neutral | HK$337.24M | ― | ― | -1.73% | -689.53% |
Clover Biopharmaceuticals Ltd. Corporate Events
Clover Biopharmaceuticals Ltd. announced that it has received an arbitration request from Gavi, seeking repayment of $224 million in advance payment amounts. Clover believes the claim is without merit and intends to defend itself vigorously, while continuing its development of the RSV vaccine candidate SCB-1019.
Clover Biopharmaceuticals Ltd. has announced its upcoming annual general meeting scheduled for June 19, 2025, in Chengdu, China. Key agenda items include the adoption of financial statements for 2024, re-election of directors, and the appointment of auditors. Additionally, the meeting will address resolutions to authorize the board to manage share capital, which may impact the company’s future financial strategies and shareholder value.
Clover Biopharmaceuticals Ltd. announced the grant of 5,964,000 options and 9,016,500 restricted stock units (RSUs) to eligible participants under its Post-IPO Share Option Plan and RSU Scheme. The options and RSUs are part of the company’s strategy to incentivize and retain talent by aligning employee and stakeholder interests with company performance. The options have a 10-year validity, with vesting conditions tied to group and individual performance targets, reflecting the company’s commitment to achieving long-term growth and operational success.
Clover Biopharmaceuticals Ltd. announced its annual results for the year ended December 31, 2024, revealing a significant decrease in cash and bank balances due to net cash outflows from loan repayments and investments in R&D. The company’s revenue remained stable, with increased sales of AdimFlu-S (QIS) offset by sales returns. Notably, there was a substantial decrease in other income and gains due to reduced funding recognition from CEPI. The company also reported decreased expenses across various categories, reflecting cost-saving initiatives and strategic optimization, particularly in R&D, where a focus on respiratory vaccines was prioritized.
Clover Biopharmaceuticals Ltd. announced the postponement of its board meeting originally scheduled for March 24, 2025, to March 31, 2025. The delay is due to the need for additional time to finalize the company’s annual results for the year ended December 31, 2024, which are crucial for evaluating the payment of a final dividend.
Clover Biopharmaceuticals Ltd. has announced that its subsidiary, Clover HK, received a notice from Gavi Alliance regarding the unilateral termination of their Advance Purchase Agreement and a claim for repayment of $224 million. Clover Biopharmaceuticals disputes the claim, asserting it is without merit and plans to defend itself vigorously. The company continues to focus on advancing its RSV vaccine candidate, SCB-1019, in a re-vaccination setting and as part of a respiratory combination vaccine.
Clover Biopharmaceuticals Ltd. announced the U.S. FDA clearance for its Investigational New Drug application and the initiation of a Phase I revaccination clinical trial for its RSV vaccine candidate, SCB-1019. This trial, enrolling older adults who previously received GSK’s RSV vaccine, aims to evaluate the safety and immunogenicity of SCB-1019. The company is also planning a Phase I trial in 2025 for a combination vaccine involving RSV and other respiratory viruses, indicating its strategic expansion in the vaccine market.